Background
Materials and methods
Cell lines and lung tissue samples
Bladder tissue samples and RNA preparation
Expression profiling in cancer using cDNA microarrays
Quantitative real-time PCR
siRNA transfection and cell growth assay
Western blot analysis
BrdU labeling and immuocytochemical analysis
Immunohistochemical staining and tissue microarray
Statistical analysis
Results
MCM7 expression is significantly high in lung cancer tissues and correlated with poor prognosis in NSCLC
Total | MCM7 positive | MCM7 negative | P-value* positive vs negative | ||
---|---|---|---|---|---|
n = 331 | n = 196 | n = 135 | |||
Gender | |||||
Male | 236 | 156 | 80 | <0.0001 | |
Female | 95 | 40 | 55 | ||
Age(years) | |||||
<65 | 168 | 107 | 61 | NS | |
≧65 | 163 | 89 | 74 | ||
Histological type | |||||
ADC | 214 | 101 | 113 | ||
SCC | 78 | 63 | 15 | <0.0001† | |
Others** | 39 | 32 | 7 | ||
pT factor | |||||
T1T2 | 227 | 127 | 100 | NS | |
T3T4 | 104 | 69 | 35 | ||
pN factor | |||||
N0 | 197 | 99 | 98 | <0.0001 | |
N1+N2 | 134 | 97 | 37 |
Variables | Hazards ratio | 95%Cl | Unfavorable/Favorable | P-value* | |
---|---|---|---|---|---|
Univariate analysis | |||||
MCM7 | 1.546 | 1.134-2.110 | Positive/Negative | 0.0059 | |
Age (years) | 1.354 | 1.008-1.818 | 65 ≧/< 65 | 0.0442 | |
Gender | 1.435 | 1.020-2.020 | Female/Male | 0.0378 | |
Histological type | 1.530 | 1.138-2.056 | nonADC/ADC | 0.0048 | |
pT factor | 1.647 | 1.217-2.232 | T3T4/T1T2 | 0.0013 | |
pN factor | 2.617 | 1.945-3.521 | N1+N2/N0 | <0.0001 | |
Variables
|
Hazards ratio
|
95%Cl
|
Unfavorable/Favorable
| P -value* | |
Multivariate analysis | |||||
MCM7 | 0.935 | 0.665-1.314 | Positive/Negative | NS | |
Age (years) | 1.576 | 1.166-2.130 | 65 ≧/< 65 | 0.0031 | |
Gender | 0.801 | 0.553-1.159 | Female/Male | NS | |
Histological type | 0.819 | 0.589-1.140 | nonADC/ADC | NS | |
pT factor | 1.538 | 1.131-2.092 | T3T4/T1T2 | 0.006 | |
pN factor | 2.577 | 1.887-3.521 | N1+N2/N0 | <0.0001 |
MCM7 is overexpressed in bladder and various types of cancers
Ratio (Tumor/Normal) | ||||
---|---|---|---|---|
Tissue type | Case (n) | Count > 2 (T/N) | Count > 3 (T/N) | Count > 5 (T/N) |
NSCLC | 37 | 9 (24.3%) | 4 (10.8%) | 0 (0%) |
SCLC | 15 | 12 (80.0%) | 9 (60.0%) | 2 (13.3%) |
Esophageal cancer | 62 | 37 (59.7%) | 28 (45.2%) | 12 (19.4%) |
Colorectal cancer | 42 | 17 (40.5%) | 9 (21.4%) | 0 (0%) |
Liver cancer | 20 | 8 (40.0%) | 5 (25.0%) | 1 (5.0%) |
Pancreatic cancer | 18 | 8 (44.4%) | 3 (16.7%) | 1 (5.6%) |
Bladder cancer | 34 | 33 (97.1%) | 23 (67.6%) | 11 (34.4%) |
Testicular cancer | 13 | 10 (76.9%) | 7 (53.8%) | 4 (30.8%) |
AML | 56 | 18 (32.1%) | 6 (10.7%) | 1 (1.8%) |
Osteosarcoma | 25 | 13 (52.0%) | 6 (24.0%) | 2 (8.0%) |
Soft tissue tumor | 63 | 51 (81.0%) | 35 (55.6%) | 16 (25.4%) |